U.S. markets closed

BioXcel Therapeutics, Inc. (BTAI)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
37.79+0.28 (+0.75%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Engulfing Line (Bullish)

Engulfing Line (Bullish)

Previous Close37.51
Open37.03
Bid36.20 x 1000
Ask37.80 x 800
Day's Range36.58 - 37.89
52 Week Range28.00 - 71.50
Volume439,953
Avg. Volume376,065
Market Cap930.843M
Beta (5Y Monthly)1.08
PE Ratio (TTM)N/A
EPS (TTM)-4.06
Earnings DateAug 12, 2021 - Aug 16, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est104.82
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • BioXcel Therapeutics to Host Virtual Commercial Day on June 25, 2021
    GlobeNewswire

    BioXcel Therapeutics to Host Virtual Commercial Day on June 25, 2021

    Live webcast to be held on June 25th from 12:00 PM ET – 1:30 PM ETNEW HAVEN, Conn., June 18, 2021 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. ("BioXcel" or the "Company") (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced that the Company will host a virtual Commercial Day on Friday, June 25, 2021, from 12:00 PM ET – 1:30 PM ET. The event aims to provid

  • BioXcel Therapeutics to Participate in Three Upcoming Healthcare Investor Conferences
    GlobeNewswire

    BioXcel Therapeutics to Participate in Three Upcoming Healthcare Investor Conferences

    NEW HAVEN, Conn., May 26, 2021 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. ("BioXcel" or the "Company") (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced that Dr. Vimal Mehta, Founder and Chief Executive Officer of BioXcel, will participate in fireside chats at three upcoming virtual healthcare investor conferences. Presentation Details: Event: Jefferies Virtual Healthcare ConferenceDate: Wednesday, June 2, 2021Time: 10:30 AM ET Event: Goldman Sachs 42nd Annual Global Healthcare ConferenceDate: Wednesday, June 9, 2021Time: 4:40 PM ET Event: BofA Securities Napa Biopharma ConferenceDate: Monday, June 14, 2021Time: 11:30 AM ET Live webcasts of the fireside chats will be accessible through the Investors section of the Company's website at www.bioxceltherapeutics.com. Following the conferences, the webcasts will be archived on the Company’s website for at least 30 days. About BioXcel Therapeutics, Inc. BioXcel Therapeutics, Inc. is a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. BioXcel’s drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. BioXcel’s two most advanced clinical development programs are BXCL501, an investigational, proprietary, orally dissolving thin film formulation of dexmedetomidine for the treatment of agitation and opioid withdrawal symptoms, and BXCL701, an investigational, orally administered, systemic innate immunity activator in development for the treatment of aggressive forms of prostate cancer and advanced solid tumors that are refractory or treatment naïve to checkpoint inhibitors. For more information, please visit www.bioxceltherapeutics.com. Contact Information: BioXcel Therapeutics, Inc.www.bioxceltherapeutics.com Investor Relations:Mary ColemanBioXcel Therapeutics, VP of Investment RelationsMColeman@bioxceltherapeutics.com 1.475.238.6837 John GrazianoSolebury Troutjgraziano@soleburytrout.com 1.646.378.2942 Media: Julia DeutschSolebury Troutjdeutsch@soleburytrout.com 1.646.378.2967

  • Could The BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Ownership Structure Tell Us Something Useful?
    Simply Wall St.

    Could The BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Ownership Structure Tell Us Something Useful?

    The big shareholder groups in BioXcel Therapeutics, Inc. ( NASDAQ:BTAI ) have power over the company. Insiders often...